Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of a placebo (an inert substance with no pharmacological effect) and lidocaine, a local anesthetic and class Ib antiarrhythmic agent. Lidocaine works by blocking voltage-gated sodium channels in neuronal cell membranes, thereby inhibiting nerve impulse conduction and providing local anesthesia or antiarrhythmic effects. The combination "placebo + lidocaine" is not itself a marketed pharmaceutical product but refers to the use of both agents in clinical trials as separate arms for comparison—one group receives active lidocaine, while another receives an inert placebo[1][4]. Lidocaine is used for local anesthesia in various procedures, treatment of ventricular arrhythmias, and pain management (e.g., postherpetic neuralgia)[5][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placebo + lidocaine.